A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression

Giotopoulos et al. report a novel mouse model that closely mimics the natural progression of human chronic myeloid leukemia to blast crisis, and use this model to identify novel candidate genes and pathways that, in combination with BCR-ABL, drive disease progression.

• Publication year

  2015

• Venue

  Journal of Experimental Medicine

• Publication date

  2015-09-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1084/jem.20141661PMID 26304963PMCID 4577832
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.

  2014cited by this paper
• Discovery of somatic mutations in the progression of chronic myeloid leukemia by whole-exome sequencing.

  2014cited by this paper
• Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.

  2014influential reference
• Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)

  2014cited by this paper
• JAK 2 / STAT 5 inhibition by nilotinib with ruxolitinib contributes to the elimination of chronic phase CML CD 34 + cells in vitro and in vivo

  2014cited by this paper
• Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

  2013cited by this paper
• Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.

  2013cited by this paper
• Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool

  2013cited by this paper
• Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex

  2013cited by this paper
• JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia.

  2013cited by this paper
• ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia

  2013cited by this paper
• Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia.

  2013influential reference
• PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

  2013cited by this paper
• Cancer Gene Discovery: Exploiting Insertional Mutagenesis

  2013cited by this paper
• Targeting of the MNK–eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function

  2013cited by this paper
• The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity

  2012cited by this paper
• ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.

  2012cited by this paper
• Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.

  2012cited by this paper
• Targeting epigenetic readers in cancer.

  2012cited by this paper
• Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia.

  2012cited by this paper
• The role of mutations in epigenetic regulators in myeloid malignancies

  2012cited by this paper
• The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

  2012cited by this paper
• Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia.

  2012cited by this paper
• Insertional mutagenesis identifies multiple networks of co-operating genes driving intestinal tumorigenesis

  2011influential reference
• Expression patterns of microRNAs associated with CML phases and their disease related targets

  2011cited by this paper
• CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.

  2011cited by this paper
• Chronic myeloid leukemia

  2011cited by this paper
• The Transcriptional Coactivator Cbp Regulates Self-Renewal and Differentiation in Adult Hematopoietic Stem Cells

  2011cited by this paper
• Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

  2011cited by this paper
• Modeling the evolution of ETV6-RUNX1-induced B-cell precursor acute lymphoblastic leukemia in mice.

  2011cited by this paper
• A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases

  2011influential reference
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.

  2011cited by this paper
• Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice

  2011cited by this paper
• Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias.

  2011cited by this paper
• Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study

  2011cited by this paper
• Chronic myeloid leukemia: mechanisms of blastic transformation.

  2010cited by this paper
• PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice.

  2010cited by this paper
• A comprehensive catalogue of somatic mutations from a human cancer genome

  2010cited by this paper
• High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression

  2010influential reference
• Molecular characterization and prognostic significance of FLT3 in CML progression.

  2010cited by this paper
• In vitro anti‐leukaemia activity of sphingosine kinase inhibitor

  2009cited by this paper
• Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia

  2009cited by this paper
• Clustering of aberrations to specific chromosomes in human neoplasms

  2009cited by this paper
• Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms.

  2009cited by this paper
• Enhanced expression of p210BCR/ABL and aberrant expression of Zfp423/ZNF423 induce blast crisis of chronic myelogenous leukemia.

  2009cited by this paper
• Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials

  2009cited by this paper
• A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites

  2009cited by this paper
• A small cell lung cancer genome reports complex tobacco exposure signatures

  2009cited by this paper
• Treatment of chronic myeloid leukemia in blast crisis

  2008cited by this paper
• BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

  2008cited by this paper
• Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors

  2008cited by this paper
• Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice

  2008cited by this paper
• Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.

  2008cited by this paper
• Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis.

  2008influential reference
• Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells.

  2007cited by this paper
• Leukemia

  2007cited by this paper
• The Biology of CML blast crisis.

  2007cited by this paper
• Leukemia stem cells in a genetically defined murine model of blast-crisis CML.

  2007cited by this paper
• Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

  2006cited by this paper
• Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.

  2006cited by this paper
• Detecting Statistically Significant Common Insertion Sites in Retroviral Insertional Mutagenesis Screens

  2006cited by this paper
• Gene expression changes associated with progression and response in chronic myeloid leukemia.

  2006cited by this paper
• Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.

  2006cited by this paper
• Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.

  2005cited by this paper
• From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

  2005cited by this paper
• Overlapping expression of Runx1(Cbfa2) and Runx2(Cbfa1) transcription factors supports cooperative induction of skeletal development

  2005cited by this paper
• Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.

  2005influential reference
• Role of Dok-1 and Dok-2 in Myeloid Homeostasis and Suppression of Leukemia

  2004cited by this paper
• The biology of CML blast crisis.

  2004cited by this paper
• Effect of Mutational Inactivation of Tyrosine Kinase Activity on BCR/ABL-Induced Abnormalities in Cell Growth and Adhesion in Human Hematopoietic Progenitors

  2004cited by this paper
• Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.

  2004cited by this paper
• Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome.

  2003cited by this paper
• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

  2003cited by this paper
• Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

  2003cited by this paper
• Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

  2002cited by this paper
• Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice.

  2002cited by this paper
• Bethesda proposals for classification of lymphoid neoplasms in mice.

  2002cited by this paper
• A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9

  2002cited by this paper
• A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector.

  2001cited by this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper
• The transcriptional program of a human B cell line in response to Myc.

  2001cited by this paper
• Reversibility of acute B-cell leukaemia induced by BCR–ABL1

  2000cited by this paper
• Homozygous Deletions of the p 16 Tumor-Suppressor Gene Are Associated With Lymphoid Transformation of Chronic Myeloid Leukemia

  2000cited by this paper
• Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

  2000cited by this paper
• Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.

  2000cited by this paper
• The molecular biology of chronic myeloid leukemia.

  2000cited by this paper
• An SCL 3' enhancer targets developing endothelium together with embryonic and adult haematopoietic progenitors.

  1999cited by this paper
• High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase.

  1998cited by this paper
• Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias.

  1998cited by this paper
• A BCR-ABL(p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product.

  1997cited by this paper
• CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins.

  1997cited by this paper
• Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase.

  1996cited by this paper
• Blastic transformation of p 53-deficient bone marrow cells by p 210 bcr / abl tyrosine kinase ( oncogene y tumor suppressor gene y leukemia

  1996cited by this paper
• Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis.

  1996cited by this paper
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  1996cited by this paper
• The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia.

  1995cited by this paper
• Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia.

  1995cited by this paper
• Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.

  1995cited by this paper
• Expression of GATA-1 mRNA in human myeloid leukemic cells.

  1994cited by this paper

• Potential signaling pathways, biomarkers, natural drugs, and chronic myeloid leukemia therapeutics

  2025cites this paper
• Exploring transposable elements: new horizons in cancer diagnostics and therapeutics

  2025cites this paper
• Case Report: ASXL1, RUNX1, and IDH1 mutation in tyrosine kinase-independent resistant chronic myeloid leukemia progressing to chronic myelomonocytic leukemia-like accelerated phase

  2023cites this paper
• c‐myb is involved in CML progression and is a therapeutic target in the zebrafish CML model

  2022cites this paper
• Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers

  2021cites this paper
• Harnessing the Power of Induced Pluripotent Stem Cells and Gene Editing Technology: Therapeutic Implications in Hematological Malignancies

  2021cites this paper
• SETBP1 overexpression acts in the place of class-defining mutations to drive FLT3-ITD-mutant AML.

  2021cites this paper
• Chronic myeloid leukemia stem cells: targeting therapeutic implications

  2021influential citation
• The Biology and Pathogenesis of Chronic Myeloid Leukaemia

  2021cites this paper
• CML: new tools to answer old questions.

  2020cites this paper
• The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias

  2020cites this paper
• In vivo functional screening for systems-level integrative cancer genomics

  2020cites this paper
• Transposon Insertion Mutagenesis in Mice for Modeling Human Cancers: Critical Insights Gained and New Opportunities

  2020cites this paper
• The chronic myeloid leukaemia story in the United Kingdom since 1960

  2020cites this paper
• Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage—Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities

  2020influential citation
• In vivo functional screening for systems-level integrative cancer genomics

  2020cites this paper
• Response and Resistance to BCR-ABL1-Targeted Therapies.

  2020cites this paper
• Sleeping Beauty Mouse Models of Cancer: Microenvironmental Influences on Cancer Genetics

  2019influential citation
• Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML

  2019cites this paper
• PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice

  2019cites this paper
• The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation

  2019cites this paper
• Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia

  2019cites this paper
• Molecular characterization of acute myeloid leukemia by Next Generation Sequencing: identification of novel biomarkers and targets of personalized therapies

  2018cites this paper
• Xiao-AiPing inhibits proliferation and induces apoptosis of chronic myeloid leukemia cells through downregulating β-catenin signaling pathway

  2018cites this paper
• Studying Side Effects of Tyrosine Kinase Inhibitors in a Juvenile Rat Model with Focus on Skeletal Remodeling

  2017cites this paper
• Combined inhibition of β-catenin and Bcr–Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo

  2017cites this paper
• Preclinical approaches in chronic myeloid leukemia: from cells to systems

  2017cites this paper
• Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors

  2017cites this paper
• Overview of the Use of Murine Models in Leukemia and Lymphoma Research

  2017cites this paper
• Gynecological tissue homeostasis and tumorigenesis studies using mouse models

  2017influential citation
• Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms

  2016cites this paper
• Targeting Drug Resistance in Chronic Myeloid Leukemia: A Dissertation

  2016cites this paper
• GEMMs addressing Pax5 loss-of-function in childhood pB-ALL.

  2016cites this paper
• Mouse models for pre-clinical drug testing in leukemia

  2016influential citation
• Slit-Robo GTPase-Activating Protein 2 as a metastasis suppressor in osteosarcoma

  2016cites this paper
• Management of Advanced-Phase Chronic Myelogenous Leukemia.

  2016cites this paper
• New Mouse Models to Investigate the Efficacy of Drug Combinations in Human Chronic Myeloid Leukemia.

  2016cites this paper
• Epithelial IKKα licenses ILC3s to defend the intestinal barrier

  2015cites this paper